newsfilter
← Latest News
GlobeNewswire·

Icosavax Provides Corporate Update and Anticipated Milestones for 2023

- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company's VLP platform - - Phase 1 study of IVX-A12 (a bivalent